Physician profile
Richard Mclean
NPI 1871571158
$2,382.01
in general payments reported to CMS, 2019-2025
14 companies · $573 in 2025
The $573 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $71.70 · 2021: $450 · 2022: $115 · 2023: $585 · 2024: $211 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,096.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $286.30 | 2019-2021 | |
| Boston Scientific Corporation | $246.05 | 2023-2025 | Watchman, Watchman Flx |
| Stryker Corporation | $149.50 | 2019 | |
| Lilly USA, LLC | $140.16 | 2019-2025 | |
| Novo Nordisk INC | $139.31 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $77.51 | 2022-2023 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $60.65 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.74 | 2021-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $36.77 | 2021 | |
| Pfizer INC. | $35.18 | 2019-2020 | |
| Astellas Pharma US INC | $26.78 | 2023 | Myrbetriq |
| Dexcom, INC. | $22.57 | 2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.